590 related articles for article (PubMed ID: 33233817)
1. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
Schumann S; Kaiser A; Nicoletti F; Mangano K; Fagone P; van Wijk E; Yan Y; Schulz P; Ludescher B; Niedermaier M; von Wegerer J; Rauch P; Setz C; Schubert U; Brysch W
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233817
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
Front Immunol; 2020; 11():2056. PubMed ID: 32973814
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D
Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
6. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
7. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
Lisi L; Lacal PM; Barbaccia ML; Graziani G
Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM
EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968
[TBL] [Abstract][Full Text] [Related]
9. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
10. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
11. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
12. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Jeon S; Ko M; Lee J; Choi I; Byun SY; Park S; Shum D; Kim S
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366720
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
14. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
16. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Gordon DE; Jang GM; Bouhaddou M; Xu J; Obernier K; White KM; O'Meara MJ; Rezelj VV; Guo JZ; Swaney DL; Tummino TA; Hüttenhain R; Kaake RM; Richards AL; Tutuncuoglu B; Foussard H; Batra J; Haas K; Modak M; Kim M; Haas P; Polacco BJ; Braberg H; Fabius JM; Eckhardt M; Soucheray M; Bennett MJ; Cakir M; McGregor MJ; Li Q; Meyer B; Roesch F; Vallet T; Mac Kain A; Miorin L; Moreno E; Naing ZZC; Zhou Y; Peng S; Shi Y; Zhang Z; Shen W; Kirby IT; Melnyk JE; Chorba JS; Lou K; Dai SA; Barrio-Hernandez I; Memon D; Hernandez-Armenta C; Lyu J; Mathy CJP; Perica T; Pilla KB; Ganesan SJ; Saltzberg DJ; Rakesh R; Liu X; Rosenthal SB; Calviello L; Venkataramanan S; Liboy-Lugo J; Lin Y; Huang XP; Liu Y; Wankowicz SA; Bohn M; Safari M; Ugur FS; Koh C; Savar NS; Tran QD; Shengjuler D; Fletcher SJ; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; Sharp PP; Wenzell NA; Kuzuoglu-Ozturk D; Wang HY; Trenker R; Young JM; Cavero DA; Hiatt J; Roth TL; Rathore U; Subramanian A; Noack J; Hubert M; Stroud RM; Frankel AD; Rosenberg OS; Verba KA; Agard DA; Ott M; Emerman M; Jura N; von Zastrow M; Verdin E; Ashworth A; Schwartz O; d'Enfert C; Mukherjee S; Jacobson M; Malik HS; Fujimori DG; Ideker T; Craik CS; Floor SN; Fraser JS; Gross JD; Sali A; Roth BL; Ruggero D; Taunton J; Kortemme T; Beltrao P; Vignuzzi M; García-Sastre A; Shokat KM; Shoichet BK; Krogan NJ
Nature; 2020 Jul; 583(7816):459-468. PubMed ID: 32353859
[TBL] [Abstract][Full Text] [Related]
17. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
18. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
19. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
20. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]